TANDA, ENRICA TERESA
 Distribuzione geografica
Continente #
EU - Europa 1.664
AS - Asia 168
NA - Nord America 44
SA - Sud America 28
AF - Africa 3
Totale 1.907
Nazione #
IT - Italia 1.655
SG - Singapore 64
VN - Vietnam 53
CN - Cina 40
US - Stati Uniti d'America 39
BR - Brasile 20
HK - Hong Kong 4
PL - Polonia 4
AR - Argentina 3
MX - Messico 3
AT - Austria 2
RU - Federazione Russa 2
VE - Venezuela 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
AZ - Azerbaigian 1
CA - Canada 1
CO - Colombia 1
EC - Ecuador 1
FI - Finlandia 1
GY - Guiana 1
ID - Indonesia 1
IN - India 1
IQ - Iraq 1
NI - Nicaragua 1
PS - Palestinian Territory 1
TR - Turchia 1
Totale 1.907
Città #
Genoa 1.006
Genova 249
Vado Ligure 235
Rapallo 145
Ashburn 27
Ho Chi Minh City 22
Beijing 14
Hanoi 6
Milan 5
Singapore 5
Hong Kong 4
São Paulo 4
Biên Hòa 3
Bordighera 3
Brugherio 3
Goiânia 3
Bắc Giang 2
Haiphong 2
Mexico City 2
Phoenix 2
Turin 2
Verona 2
Vienna 2
Villasanta 2
Ankara 1
Annapolis 1
Baku 1
Barquisimeto 1
Belo Campo 1
Bologna 1
Boston 1
Bắc Ninh 1
Can Tho 1
Caracas 1
Curitiba 1
Da Nang 1
Diamantina 1
Georgetown 1
Gobernador Virasoro 1
Greensboro 1
Hefei 1
Honolulu 1
Houston 1
Johannesburg 1
Juneau 1
Lappeenranta 1
Los Angeles 1
Luanda 1
Managua 1
Mendoza 1
Montes Claros 1
Montreal 1
Moscow 1
Najaf 1
Ninh Bình 1
Pacaraima 1
Paulista 1
Phúc Yên 1
Phủ Lý 1
Piracicaba 1
Pittsburgh 1
Querétaro 1
Quito 1
Quảng Nam Province 1
Quận Năm 1
Ramallah 1
Rio do Oeste 1
Salvador 1
San Justo 1
Santiago 1
Santiago de Cali 1
Sorocaba 1
São Miguel do Guaporé 1
Thái Bình 1
Thái Nguyên 1
Tianjin 1
Volta Redonda 1
Warsaw 1
Totale 1.804
Nome #
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 175
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients 146
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization 121
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab 119
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 101
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient 97
Efficacy of braf and mek inhibition in patients with braf‐mutant advanced melanoma and germline cdkn2a pathogenic variants 96
How to make immunotherapy an effective therapeutic choice for uveal melanoma 86
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors? 75
Development of a gene panel for hotspot mutation and copy number alterations based uveal melanoma prognostication. 71
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting 69
Primary endobronchial melanoma: a case report and clinical management indications 67
Identification of prognostic and predictive liquid biopsy biomarkers in patients with Cutaneous Squamous Cell Carcinoma (CSCC) treated with Cemiplimab. 66
Assessing Determinants of Response to PARP Inhibition in Germline ATM Mutant Melanoma 65
Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis 63
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup 59
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review 55
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma 55
Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma 52
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale? 50
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study 49
The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors 45
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy 44
Machine Learning Methods for Gene Selection in Uveal Melanoma 42
Current status and perspectives in immunotherapy for metastatic melanoma 39
The adjuvant treatment revolution for high-risk melanoma patients 36
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses 15
Identification of prognostic liquid biopsy biomarkers in patients with cutaneous squamous cell carcinoma treated with cemiplimab 8
Immune-related osteitis mimicking femoral head osteonecrosis during dual checkpoint blockade: a case report 5
Totale 1.971
Categoria #
all - tutte 8.092
article - articoli 7.737
book - libri 0
conference - conferenze 224
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.053


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202151 0 0 0 0 0 3 11 7 7 11 11 1
2021/202294 11 1 3 8 5 5 2 14 6 22 3 14
2022/2023174 13 18 2 11 37 20 0 17 20 1 27 8
2023/2024160 6 9 6 19 7 33 10 4 9 14 9 34
2024/2025627 30 48 14 53 70 55 42 96 14 26 100 79
2025/2026744 163 40 163 153 179 46 0 0 0 0 0 0
Totale 1.971